Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 13/20 | 0.48 |
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6994822 | 0.93 | PDE9A (0.49) | PDE9APDE2APDE1CKMT2A | |
| SCHEMBL6992804 | 0.92 | PDE9A (0.52) | PDE9APDE2APDE1C | |
| SCHEMBL6994147 | 0.91 | PDE9A (0.46) | PDE9APDE2APDE1CLMNAKMT2A | |
| SCHEMBL6993084 | 0.91 | PDE9A (0.46) | PDE9APDE2APDE1CKMT2A | |
| SCHEMBL6991004 | 0.90 | PDE9A (0.45) | PDE9APDE2APDE1CLMNAKMT2A | |
| SCHEMBL6990625 | 0.90 | PDE9A (0.45) | PDE9APDE2APDE1CKMT2A | |
| SCHEMBL6997919 | 0.90 | PDE9A (0.46) | PDE9APDE2APDE1CKMT2A | |
| SCHEMBL7000731 | 0.89 | PDE2A (0.57) | PDE9APDE2APDE1C | |
| SCHEMBL6995575 | 0.86 | PDE9A (0.46) | PDE9APDE1CADORA3MEN1LMNA | |
| SCHEMBL7892432 | 0.86 | PDE9A (0.46) | PDE9APDE2APDE1CADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973774-B1 | 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES | BAYER AG (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-6174884-B1 | CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-16 | — | — | US | disclosed |